病毒学抑制的HIV感染成人社区获得性肺炎链球菌肺炎:一项匹配病例对照研究
本研究在西班牙巴塞罗那医院开展匹配病例对照研究(2001-2016),比较50例HIV感染(病毒学抑制、CD4+>350/mm3、接受ART)与100例非HIV感染住院患者的肺炎链球菌肺炎。病例组流感(14% vs 2%,P=.007)和肺炎链球菌疫苗接种率(10% vs 1%,P=.016)更高,乙肝病毒合并感染率更高(6% vs 0%,P=.036)。两组ICU入住率(18% vs 27%,P=.22)、机械通气需求(12% vs 8%,P=.43)、住院时长(7天 vs 7天,P=.76)和30天死亡率(均为0%)均无显著差异。结论认为此类HIV患者肺炎链球菌肺炎并不更严重或预后更差,支持其无需不同于一般人群的治疗、入院或照护场所。
要点
- 病毒学抑制且CD4+>350/mm3的HIV感染者,肺炎链球菌肺炎的ICU入住率与非HIV感染者无显著差异(18% vs 27%,P=.22)。
- 两组机械通气需求(12% vs 8%,P=.43)、住院时长(7天 vs 7天,P=.76)和30天死亡率(均为0%)均无显著差异。
- 病例组流感发生率更高(14% vs 2%,P=.007),肺炎链球菌疫苗接种率更高(10% vs 1%,P=.016)。
- 病例组乙肝病毒合并感染率更高(6% vs 0%,P=.036)。
- 作者认为此类患者无需不同于一般人群的治疗、入院或照护场所。
适用人群与场景
- 纳入病毒学抑制、接受ART、CD4+ T细胞计数>350 cells/mm3的HIV感染成人住院肺炎链球菌肺炎患者(病例组)。
- 对照为非HIV感染住院肺炎链球菌肺炎患者,按年龄(±10岁)、性别、合并症和同一日历期间肺炎诊断匹配。
- 研究场所为西班牙巴塞罗那医院,研究期间为2001-2016年。
研究设计与关键结果
- 研究类型为匹配病例对照研究,纳入50例HIV感染病例和100例非HIV感染对照。
- 病例组流感发生率14% vs 对照组2%(P=.007),肺炎链球菌疫苗接种率10% vs 1%(P=.016),乙肝病毒合并感染率6% vs 0%(P=.036)。
- 两组ICU入住率18% vs 27%(P=.22),机械通气需求12% vs 8%(P=.43),住院时长7天 vs 7天(P=.76),30天死亡率均为0%。
- 未发现病例组较对照组临床表现更严重或临床结局更差的证据。
证据类型、等级与局限
- 证据类型为匹配病例对照研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,病毒学抑制且CD4+>350 cells/mm3的HIV感染者发生需住院的肺炎链球菌肺炎时,无需不同于一般人群的治疗、入院或照护场所。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The study aimed to investigate whether the clinical presentations and outcomes (length of stay, ICU admission, and 30-day mortality) of pneumococcal pneumonia in virologically suppressed patients who were HIV-infected on ART with a CD4+ T-cell count > 350 cells/mm3 are comparable to those seen in patients with HIV, using a case-control design.
METHODS: A case-control study was carried out in Hospital Clinic, Barcelona, Spain (2001-2016). Control patients were matched by age (±10 years), sex, comorbidities, and pneumonia diagnosis in the same calendar period. Clinical presentation and outcomes of pneumococcal pneumonia in patients who were and were not infected with HIV were compared.
RESULTS: Pneumococcal pneumonia was studied in 50 cases (HIV infection) and 100 control patients (non-HIV infection). Compared with the control patients, case patients had higher rates of influenza (14% vs 2%, P = .007) and pneumococcal vaccination (10% vs 1%, P = .016). The group of cases also presented a higher rate of coinfection with hepatitis B virus (6% vs 0%, P = .036). Both groups presented similar ICU admission (18% vs 27%, P = .22), need for mechanical ventilation (12% vs 8%; P = .43), length of stay (7 days vs 7 days, P = .76), and 0% of 30-day mortality. No evidence was found of a more severe presentation or a worse clinical outcome in cases than in control patients.
CONCLUSIONS: Pneumococcal pneumonia episodes requiring hospitalization in virologically suppressed patients with HIV with > 350 CD4+ T-cell count/mm3 were neither more severe nor had worse prognosis compared with uninfected patients. These results support the fact that such patients do not need treatment, admission, or care sites different to the general population.
TRIAL REGISTRY: ClinicalTrials.gov; No. 2009/5451; URL: www.clinicaltrials.gov.
参考来源
- Cillóniz C, Torres A, Manzardo C, et al. Community-Acquired Pneumococcal Pneumonia in Virologically Suppressed HIV-Infected Adult Patients: A Matched Case-Control Study. Chest. 2017. PMID: 28302496. doi:10.1016/j.chest.2017.03.007
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。